Advanced Cell Diagnostics’ RNAscope^TM in situ hybridization (ISH) platforms are widely utilized for high resolution tissue-based and cell-specific analysis of targets and biomarkers. The RNAscope ISH platform is clinically validated and enables quantitative expression analysis that has repeatedly been proven to better stratify treatment-responsive and non-responsive patients in therapeutic clinical trials compared to traditional methods such as IHC and qPCR.

RNAscope is often more sensitive than IHC and provides cell-specific biomarker data in complex tissue microenvironments that qPCR cannot. A further advantage is speed: RNAscope biomarker assays can be verified and ready for use on clinical biopsies in a matter of weeks.

• Biomarker validation to accelerate translation of assays into clinical development in a GCLP setting
• Assay feasibility and development - sensitivity, specificity, and precision testing (repeatability & reproducibility)
• Development of pathologist scoring and HALO^TM image analysis algorithms for biomarker assessment
• Established protocols for clinical assay transfer to CLIA-certified labs for prospective use
• RNAscope multiplexing and validated protocols for co-detection of biomarkers and immune cell markers
• Quantifiable, cell-specific, single-molecule detection of RNA biomarkers in tumor biopsies
• Superior performance against traditional methods, e.g., IHC, qPCR
• Application in small molecule, biologic and cell therapy biomarkers